Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
06:20am, Sunday, 09'th Jun 2024
Cathie Wood loves bargains on potential long-term winners -- especially when the company is an innovator. One of her favorite technologies in healthcare is gene editing, and she's been loading up on t
These 2 Words Are Why Intellia Therapeutics Could Be a Smart Buy Right Now
07:25am, Saturday, 08'th Jun 2024
Intellia Therapeutics has a gene editing therapy that looks to be quite effective. That's favorable for the program's chances of getting approved.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:05am, Thursday, 06'th Jun 2024
Wood added to her positions in Reddit, Intellia Therapeutics, and PagerDuty on Wednesday. Wood's Ark Invest was a buyer of Reddit the day it went public in March.
The 3 Best Biotech Stocks to Buy in June 2024
01:35pm, Wednesday, 05'th Jun 2024
The biotech sector, under the life sciences umbrella, exited 2023 with 41 bankruptcies. This was not surprising given the disparity between biotech's high-capital requirements and rising interest rate
Intellia Therapeutics Presents Promising In Vivo CRISPR Results
07:11am, Wednesday, 05'th Jun 2024
Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering poten
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
12:25pm, Tuesday, 04'th Jun 2024
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Cathie Wood Is Buying the Dip on These 2 Biotech Stocks. Should You?
06:45am, Tuesday, 04'th Jun 2024
Buying the dip in a promising stock can be an effective strategy. CRISPR Therapeutics has a long way to go before becoming profitable.
CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on revolutionizing medicine with CRISPR-based the
3 Of My Favorite Names On Wells Fargo's Biotech Buyout List
02:45pm, Wednesday, 29'th May 2024
Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and t
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:15am, Wednesday, 22'nd May 2024
Cathie Wood bought shares of Shopify, Intellia, and Adaptive Biotechnologies on Tuesday. Shopify has surrendered 26% of its value over the past two weeks since posting disappointing guidance.
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
10:30am, Tuesday, 14'th May 2024
From a technical perspective, Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick, as it just reached a key level of support. NTLA recently overtook the 50-day moving average, and t
Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
05:18am, Monday, 13'th May 2024
Intellia's longstanding collaboration with Regeneron is important in its value proposition. With three cutting-edge late-stage programs, NTLA is among the top tier of gene editing companies. Solid fin
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
12:30pm, Friday, 10'th May 2024
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:45am, Friday, 10'th May 2024
Wood added to her positions in Roblox, Accolade, and Intellia Therapeutics on Thursday. Roblox had a decent first quarter, but weak guidance sent the shares more than 20% lower on Thursday.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
09:40am, Thursday, 09'th May 2024
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.17 per share a year ago.
